Treatment of Mycobacterium avium-intracellulare complex Lung Disease With a Macrolide, Ethambutol, and Clofazimine

This publication has 26 references indexed in Scilit:

• Azithromycin-Containing Regimens for Treatment of Mycobacterium avium Complex Lung Disease
  Clinical Infectious Diseases, 2001
• First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol
  Thorax, 2001
• Cytokine Profiles in Immunocompetent Persons Infected withMycobacterium aviumComplex
  The Journal of Infectious Diseases, 2001
• Early Results (at 6 Months) with Intermittent Clarithromycin-Including Regimens for Lung Disease Due to Mycobacterium avium Complex
  Clinical Infectious Diseases, 2000
• Varying Dosages of Rifabutin Affect White Blood Cell and Platelet Counts in Human Immunodeficiency Virus-Negative Patients Who Are Receiving Multidrug Regimens for Pulmonary Mycobacterium avium Complex Disease
  Clinical Infectious Diseases, 1996
• Azithromycin Activity Against Mycobacterium avium Complex Lung Disease in Patients Who Were Not Infected with Human Immunodeficiency Virus
  Clinical Infectious Diseases, 1996
• Uveitis associated with rifabutin therapy
  Australian and New Zealand Journal of Ophthalmology, 1995
• Adverse Events Associated with High-Dose Rifabutin in Macrolide-Containing Regimens for the Treatment of Mycobacterium avium Complex Lung Disease
  Clinical Infectious Diseases, 1995
• Drug intolerance to high-dose clarithromycin among elderly patients
  Diagnostic Microbiology and Infectious Disease, 1993
• Infection withMycobacterium aviumComplex in Patients without Predisposing Conditions
  New England Journal of Medicine, 1989